EP3175244A4 - Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof - Google Patents

Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof Download PDF

Info

Publication number
EP3175244A4
EP3175244A4 EP15826771.6A EP15826771A EP3175244A4 EP 3175244 A4 EP3175244 A4 EP 3175244A4 EP 15826771 A EP15826771 A EP 15826771A EP 3175244 A4 EP3175244 A4 EP 3175244A4
Authority
EP
European Patent Office
Prior art keywords
compositions
treatment
methods
lymphoblastic leukemia
acute lymphoblastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15826771.6A
Other languages
German (de)
French (fr)
Other versions
EP3175244A1 (en
Inventor
Smadar Avigad
Isaac Yaniv
Keren SHICHRUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mor Research Applications Ltd
Original Assignee
Mor Research Applications Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Applications Ltd filed Critical Mor Research Applications Ltd
Publication of EP3175244A1 publication Critical patent/EP3175244A1/en
Publication of EP3175244A4 publication Critical patent/EP3175244A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141MicroRNAs, miRNAs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP15826771.6A 2014-07-30 2015-07-30 Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof Withdrawn EP3175244A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462030629P 2014-07-30 2014-07-30
PCT/IL2015/050791 WO2016016898A1 (en) 2014-07-30 2015-07-30 Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof

Publications (2)

Publication Number Publication Date
EP3175244A1 EP3175244A1 (en) 2017-06-07
EP3175244A4 true EP3175244A4 (en) 2018-06-13

Family

ID=55216853

Family Applications (2)

Application Number Title Priority Date Filing Date
EP15826672.6A Not-in-force EP3175001B1 (en) 2014-07-30 2015-07-30 Prognostic methods and systems of treatment for acute lymphoblastic leukemia
EP15826771.6A Withdrawn EP3175244A4 (en) 2014-07-30 2015-07-30 Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP15826672.6A Not-in-force EP3175001B1 (en) 2014-07-30 2015-07-30 Prognostic methods and systems of treatment for acute lymphoblastic leukemia

Country Status (4)

Country Link
US (3) US20170252364A1 (en)
EP (2) EP3175001B1 (en)
CN (1) CN107075573A (en)
WO (2) WO2016016897A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170252364A1 (en) * 2014-07-30 2017-09-07 Mor Research Applications Ltd. Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof
WO2018191747A1 (en) * 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating pulmonary arterial hypertension
CN110945128B (en) 2017-04-14 2023-11-03 代表亚利桑那大学的亚利桑那董事会 Compositions and methods for treating pulmonary fibrosis
CN110656162A (en) * 2019-09-18 2020-01-07 浙江大学 Detection method of circulating miR-1290

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016016897A1 (en) * 2014-07-30 2016-02-04 Smadar Avigad Prognostic methods and systems of treatment for acute lymphoblastic leukemia

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
ATE138106T1 (en) 1988-07-20 1996-06-15 David Segev METHOD FOR AMPLIFICATION AND DETECTION OF NUCLEIC ACID SEQUENCES
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
ES2168380T3 (en) 1994-07-15 2002-06-16 Organon Teknika Bv USE OF RNA POLYMERASE TO IMPROVE A PROCEDURE FOR AMPLIFICATION OF NUCLEIC ACID.
AU693023B2 (en) 1995-05-05 1998-06-18 Applied Biosystems, Llc Methods and reagents for combined PCR amplification and hybridization probing assay
AT402203B (en) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr METHOD FOR TRANSCRIPTION-FREE AMPLIFICATION OF NUCLEIC ACIDS
EP2369007B1 (en) 1996-05-29 2015-07-29 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions
US5736333A (en) 1996-06-04 1998-04-07 The Perkin-Elmer Corporation Passive internal references for the detection of nucleic acid amplification products
US5866336A (en) 1996-07-16 1999-02-02 Oncor, Inc. Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US5952202A (en) 1998-03-26 1999-09-14 The Perkin Elmer Corporation Methods using exogenous, internal controls and analogue blocks during nucleic acid amplification
PL2918604T3 (en) * 2008-11-07 2018-05-30 Amgen Research (Munich) Gmbh Treatment of pediatric acute lymphoblastic leukemia
GB201001950D0 (en) * 2010-02-05 2010-03-24 Binding Site Group The Ltd Infection prognostic assay
WO2012042516A2 (en) 2010-09-29 2012-04-05 Mor Research Applications Ltd. Prognostic methods, compositions and kits for prediction of acute lymphoblastic leukemia (all) relapse
US10557173B2 (en) * 2010-09-29 2020-02-11 Mor Research Applications Ltd. Prognostic methods, compositions and kits for prediction of acute lymphoblastic leukemia (ALL) relapse
CN102925575B (en) * 2012-09-29 2014-10-29 李艳 Kit for detecting protein expression indexes of test equipment list-acute myelogenous leukemia1 (TEL-AML1) fusion gene messenger ribonucleic acid (mRNA)
CN103627810A (en) * 2013-12-11 2014-03-12 厦门大学 Multiplex RT-PCR (reverse transcription-polymerase chain reaction) reagent kit for detecting leukemia BCR-ABL (Abelson proto-oncogene-breakpoint cluster region)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016016897A1 (en) * 2014-07-30 2016-02-04 Smadar Avigad Prognostic methods and systems of treatment for acute lymphoblastic leukemia

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LI X ET AL: "Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 208, no. 4, 11 April 2011 (2011-04-11), pages 663 - 675, XP002742605, ISSN: 0022-1007, DOI: 10.1084/JEM.20102384 *
NEDA MOSAKHANI: "MicroRNAs as Predictive and Prognostic Biomarkers in Human Neoplasia: With Specific Focus on Colorectal Cancer, Giant Cell Tumor of Bone, and Leukemias", 2013, Helsinki, Finland, pages 1 - 82, XP055390482, Retrieved from the Internet <URL:https://helda.helsinki.fi/bitstream/handle/10138/38570/MicroRNA.pdf?sequence=1> [retrieved on 20170713] *
See also references of WO2016016898A1 *
SMADAR AVIGAD ET AL: "miR expression profiling at diagnosis predicts relapse in pediatric precursor B-cell acute lymphoblastic leukemia : miR EXPRESSION PREDICTS RELAPSE IN PEDIATRIC ALL", GENES CHROMOSOMES & CANCER., vol. 55, no. 4, 19 December 2015 (2015-12-19), US, pages 328 - 339, XP055447140, ISSN: 1045-2257, DOI: 10.1002/gcc.22334 *
UBALDINA GALLI ET AL: "Medicinal Chemistry of Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 56, no. 16, 22 August 2013 (2013-08-22), pages 6279 - 6296, XP055446740, ISSN: 0022-2623, DOI: 10.1021/jm4001049 *

Also Published As

Publication number Publication date
US20170268070A1 (en) 2017-09-21
EP3175244A1 (en) 2017-06-07
EP3175001A4 (en) 2018-03-14
WO2016016897A1 (en) 2016-02-04
CN107075573A (en) 2017-08-18
EP3175001B1 (en) 2021-02-10
US11045489B2 (en) 2021-06-29
US20170252364A1 (en) 2017-09-07
US20190388457A1 (en) 2019-12-26
EP3175001A1 (en) 2017-06-07
WO2016016898A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
CA3281817A1 (en) Compounds and their methods of use
EP3245291A4 (en) Novel micro-dystrophins and related methods of use
CA3244408A1 (en) Therapeutic compositions, combinations, and methods of use
EP3377070A4 (en) Compounds and methods of their use
EP3194525A4 (en) Proppant compositions and methods of use
EP3218005A4 (en) Glycan-interacting compounds and methods of use
EP3212226A4 (en) Compositions and methods of use for treating metabolic disorders
EP3268018A4 (en) Bacterial compositions and methods of use thereof
EP3174894A4 (en) Compositions and methods of use for treating metabolic disorders
EP3116511A4 (en) Compositions of selenoorganic compounds and methods of use thereof
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
EP3194564A4 (en) Trichoderma compositions and methods of use
EP3137085A4 (en) Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
EP3265096A4 (en) Ophthalmic compositions and methods of use therefor
EP3125963A4 (en) Tissue filler compositions and methods of use
EP3190886A4 (en) Compositions and methods of use thereof
EP3265476A4 (en) Protoxin-ii variants and methods of use
EP3117827A4 (en) Composition for vagina and use of the composition
SG11201702554QA (en) Compositions and methods for the treatment of multiple sclerosis
EP3185872A4 (en) Formulations of testosterone and methods of treatment therewith
EP3322838A4 (en) Cleaning compositions and methods of use therefor
EP3277304A4 (en) Protoxin-ii variants and methods of use
EP3185910A4 (en) Methods and compositions for the treatment of cancer
EP3154952A4 (en) Methods and compositions for treatment of her-positive cancers
EP3134108A4 (en) Agents and methods of treatment

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

17P Request for examination filed

Effective date: 20170130

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: AVIGAD, SMADAR

Inventor name: SHICHRUR, KEREN

Inventor name: YANIV, ISAAC

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20180101ALI20180208BHEP

Ipc: C12N 15/113 20100101AFI20180208BHEP

Ipc: G01N 33/574 20060101ALI20180208BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20180515

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20060101ALI20180508BHEP

Ipc: G01N 33/574 20060101ALI20180508BHEP

Ipc: C12N 15/113 20100101AFI20180508BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20191204

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200603